Taxonomic Characterization, Antiviral Activity and Induction of Three New Kenalactams in Nocardiopsis sp. CG3
DNA, Bacterial
Antiviral Agents
Microbiology
Biochemistry
Gene
Article
03 medical and health sciences
Context (archaeology)
Methionine
FOS: Chemical sciences
RNA, Ribosomal, 16S
Biochemistry, Genetics and Molecular Biology
Health Sciences
RNA Sequencing Data Analysis
Molecular Biology
Biology
Phylogeny
Soil Microbiology
Pharmacology
0303 health sciences
Chemical Glycobiology and Therapeutic Applications
Organic Chemistry
Life Sciences
Strain (injury)
Paleontology
Nocardiopsis
Natural Products as Sources of New Drugs
Sequence Analysis, DNA
Functional Genomics
Amino acid
3. Good health
Actinobacteria
Chemistry
FOS: Biological sciences
Physical Sciences
Medicine
Anatomy
16S ribosomal RNA
DOI:
10.1007/s00284-022-02954-x
Publication Date:
2022-08-10T06:02:48Z
AUTHORS (5)
ABSTRACT
AbstractExploration of secondary metabolites secreted by new Actinobacteria taxa isolated from unexplored areas, can increase the possibility to obtain new compounds which can be developed into new drugs for the treatment of serious diseases such as hepatitis C. In this context, one actinobacterial strain, CG3, has been selected based on the results of polyphasic characterization, which indicate that it represents a new putative species within the genus Nocardiopsis. Two fractions (F2 and F3), prepared from the culture of strain CG3 in soybean medium, exhibited a pronounced antiviral activity against the HCV strain Luc-Jc1. LC–HRESIMS analysis showed different bioactive compounds in both active fractions (F2 and F3), including five polyenic macrolactams (kenalactams A-E), three isoflavone metabolites, along with mitomycin C and one p-phenyl derivative. Furthermore, feeding with 1% of methionine, lysine or alanine as a unique nitrogen source, induced the production of three novel kenalactam derivatives.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (55)
CITATIONS (4)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....